Ljung R, Petrini P, Lindgren A K, Berntorp E
Department for Coagulation Disorders, Malmö General Hospital, Sweden.
Acta Paediatr. 1992 Nov;81(11):918-20. doi: 10.1111/j.1651-2227.1992.tb12135.x.
Twelve children with a severe form of haemophilia A received a totally implantable venous access system (Port-A-Cath) to facilitate regular prophylactic treatment with factor VIII. The indication for implantation was difficulty in obtaining regular access to a peripheral vein. Postoperative bleeding around the portal site occurred in two of 12 cases. After a median duration of follow-up of 26 months (range 5-79 months), none of the systems had needed replacement due to bleeding, septicaemia or thrombosis. One child, with an inhibitor against factor VIII, had an infection at the portal site and this system was removed. None of the other children had any serious side effects. Nine of the 12 children's parents learned how to use the Port-A-Cath system, thus enabling optimal prophylactic home treatment with factor VIII to be begun early in life.
12名患有严重甲型血友病的儿童接受了完全植入式静脉通路系统(Port-A-Cath),以方便定期进行凝血因子VIII预防性治疗。植入的指征是难以定期获得外周静脉通路。12例中有2例在门静脉部位出现术后出血。中位随访时间为26个月(范围5 - 79个月),没有一个系统因出血、败血症或血栓形成而需要更换。一名对凝血因子VIII有抑制剂的儿童在门静脉部位发生感染,该系统被移除。其他儿童均未出现任何严重副作用。12名儿童中的9名家长学会了如何使用Port-A-Cath系统,从而能够在儿童早期就开始进行最佳的凝血因子VIII预防性家庭治疗。